Funded Tech Companies
Oryzon Genomics
Wondering who invested in Oryzon Genomics? Private investors joined the equity holders in this innovative biopharmaceutical company.
Company Overview
Company Name
Oryzon Genomics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Sant Ferran 74
Cornellà de Llobregat, Barcelona, 08940
SE
Cornellà de Llobregat, Barcelona, 08940
SE
Phone
Website
Email Address
Company Background Information
Overview
ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
4/25/2025
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carlos Buesa
Chief Medical Officer
Michael Ropacki
Chief Operating Officer
Enric Rello
Chief Scientific Officer
Jordi Xaus
Company Investors
Browse more funded tech companies:
Share this article
About Our VC Transaction Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs